Haplo-Identical/Cord Blood Transplant for Leukemia

Recruiting in Palo Alto (17 mi)

Overseen by Leland Metheny, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Case Comprehensive Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.

Research Team

Leland Metheny, MD

Principal Investigator

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center

Eligibility Criteria

This trial is for patients with certain blood cancers or disorders, like different types of leukemia and myelodysplastic syndrome. Participants should be suitable candidates for a stem cell transplant but the specific eligibility criteria are not provided.

Inclusion Criteria

I have a specific type of blood cancer such as AML, ALL, or MDS.

I have a donor match for my transplant that meets the specific cell count requirements.

I am receiving treatment for leukemia or lymphoma outside the bone marrow or in the brain as needed.

Exclusion Criteria

My organs are not functioning well.

Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds

I had a stem cell transplant or CAR-T therapy in the last 6 months.

Treatment Details

Interventions

• Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood (CAR T-cell Therapy)

Trial Overview The study is testing whether combining two types of donors – an unmodified haplo-identical donor and cord blood – can improve survival rates without disease in patients after a stem cell transplant.

Participant Groups

Group I: Haplo-Identical / Cord Blood Transplant Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Case Comprehensive Cancer Center

Lead Sponsor

Trials

472

Recruited

33,400+

Dr. Gary K. Schwartz

Case Comprehensive Cancer Center

Chief Executive Officer since 2023

MD, FASCO

Dr. Nathan Berger

Case Comprehensive Cancer Center

Chief Medical Officer since 2020

MD